Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Price

Interventional Cardiology La Jolla, CA Medical Doctor

NPI 1659343945 CMS profile 28933

9898 Genesee Ave, La Jolla, CA 92037

Open in the dashboard

General payments

$2,308,176

1,607 records reported · program years 2019–2025

Research payments

$14,350

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,442,842 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Matthew Price of La Jolla, CA is reported in the CMS Open Payments database as having received $2,308,176 across 1,607 general payments and $14,350 in research payments paid to them. Separately, studies naming them as principal investigator received $3,442,842 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,323,916 253
2024 General $185,685 295
2023 General $162,576 302
2023 Research $14,350 3
2022 General $218,942 258
2021 General $134,743 148
2020 General $111,808 122
2019 General $170,506 229

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Price
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Matthew Price were reported at $1,323,916. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Matthew Price Interventional Cardiology median Middle half National median
2019 $170,506 $1,097 $329–$3,048 $163
2020 $111,808 $473 $161–$1,480 $114
2021 $134,743 $677 $233–$1,827 $132
2022 $218,942 $978 $333–$2,724 $149
2023 $162,576 $1,136 $382–$2,986 $160
2024 $185,685 $1,181 $395–$3,326 $164
2025 $1,323,916 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $1,335,957 295 payments
  2. Abbott Laboratories $335,195 539 payments
  3. W. L. Gore & Associates, Inc. $175,931 110 payments
  4. Philips Electronics North America Corporation $146,477 109 payments
  5. Shockwave Medical, Inc $140,376 114 payments
  6. Medtronic, Inc. $45,010 129 payments
  7. Medtronic Vascular, Inc. $32,827 38 payments
  8. Cordis US Corp. $20,471 4 payments
  9. Baylis Medical Company Inc $14,047 6 payments
  10. AstraZeneca Pharmaceuticals LP $13,119 29 payments
  11. Other $48,765 234 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $1,087,385 1 payment
  2. Consulting Fee $671,252 204 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $205,398 78 payments
  4. Travel and Lodging $112,938 220 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $93,614 28 payments
  6. Food and Beverage $50,802 1,039 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $43,451 17 payments
  8. Honoraria $31,525 7 payments
  9. Grant $11,675 4 payments
  10. Education $136 9 payments
Products named General payments · program years 2019–2025
  1. General - Therapies $1,087,385 1 payment
  2. (9520) IGT Devices Undivided $117,446 53 payments
  3. GORE CARDIOFORM Septal Occluder $98,587 50 payments
  4. WATCHMAN Access System $79,509 76 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $78,084 66 payments
  6. Product in Development $56,804 47 payments
  7. TRICLIP $51,102 38 payments
  8. Vascular Lithotripsy $45,279 20 payments
  9. AMPLATZER Occluders $42,241 33 payments
  10. MITRACLIP $41,496 45 payments
  11. Other $548,118 1,121 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $14,350 3 payments

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$480,577

Medicare's payments for the services billed

Medicare patients

628

Average age 77

Services billed

2,635

268 women, 360 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Atrial fibrillation 53%
Arthritis 53%
Heart failure 52%
Chronic kidney disease 39%
Diabetes 32%
Depression 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KENGREAL
$126 — —
ELIQUIS
$75 — —
EVKEEZA
$30 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,610 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record